Form 4: Cassava Sciences Executive Granted Stock Options

A Cassava Sciences executive, Jaren Landen, was granted 85,000 stock options on November 18, 2024, which vest over four years.

Summary

• Jaren Landen, Chief Clinical Development Officer at Cassava Sciences, was granted 85,000 stock options on November 18, 2024.
• The options have an exercise price of $27.95 per share.
• The options vest in four equal annual installments, with the first 25% vesting on November 18, 2025.
• The options expire on November 18, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of four years is typical for such grants, aligning with long-term value creation.
• The exercise price of $27.95 is specific to Cassava Sciences and would need to be compared to the market price of the stock at the time of the grant to assess its value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to increase the company's value.
• The executive benefits from the potential future value of the stock options.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cassava Sciences, SAVA, Jaren Landen, vesting